SINGAPORE -- Rapid test kits unveiled in Singapore on Friday promise to help governments worldwide assess the true spread of the coronavirus and the extent of public immunity.
The kits, called cPass, were developed after trials on COVID-19 patients in China and the city-state. They signal whether a subject has developed antibodies, or a biological response to fight the disease. This would mean they were infected at some point.
